233 related articles for article (PubMed ID: 33543377)
1. Is there any place for novel agents in treating biliary tract cancer?
Perego G; Burgio V; Nozza R; Longobardo G; Bernecich M; Luciani A; Petrelli F
Med Oncol; 2021 Feb; 38(2):19. PubMed ID: 33543377
[TBL] [Abstract][Full Text] [Related]
2. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Chiang NJ; Chen LT; Shan YS; Yeh CN; Chen MH
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33451059
[TBL] [Abstract][Full Text] [Related]
3. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
4. Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy.
Dong X; Zhang Z; Zhang Q; Chen L; Cao G; Liu C; Song T; Lu W; Zhang W
J Cancer Res Clin Oncol; 2023 May; 149(5):1917-1927. PubMed ID: 35802197
[TBL] [Abstract][Full Text] [Related]
5. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
6. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 Jul; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapies in advanced biliary tract cancers.
Tella SH; Kommalapati A; Borad MJ; Mahipal A
Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy: A Sharp Curve Turn at the Corner of Targeted Therapy in the Treatment of Biliary Tract Cancers.
Al Mahmasani L; Harding JJ; Abou-Alfa G
Hematol Oncol Clin North Am; 2024 Jun; 38(3):643-657. PubMed ID: 38423933
[TBL] [Abstract][Full Text] [Related]
9. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
11. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
Rizzo A
Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
[No Abstract] [Full Text] [Related]
12. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
13. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
16. Emerging treatment strategies in hepatobiliary cancer.
Guven DC; Yildirim HC; Chalabiyev E; Kus F; Yilmaz F; Yasar S; Akyildiz A; Aktas BY; Yalcin S; Dizdar O
Expert Rev Anticancer Ther; 2023 Mar; 23(3):243-256. PubMed ID: 36803258
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
18. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?
Serrano Uson Junior PL; Bekaii-Saab T
Immunotherapy; 2023 May; 15(7):531-540. PubMed ID: 37096922
[TBL] [Abstract][Full Text] [Related]
20. Continuum of care for advanced biliary tract cancers.
Vienot A; Neuzillet C
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):810-824. PubMed ID: 32586782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
